[1]张 伟,王巧争,陈晓伟,等.Budd- Chiari综合征患者介入开通术后再狭窄处理和远期随访结果[J].介入放射学杂志,2020,29(09):883-887.
 ZHANG Wei,WANG Qiaozheng,CHEN Xiaowei,et al.Management of postoperative restenosis in patients with Budd-Chiari syndrome after interventional recanalization and its long-term follow-up results[J].journal interventional radiology,2020,29(09):883-887.
点击复制

Budd- Chiari综合征患者介入开通术后再狭窄处理和远期随访结果()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
29
期数:
2020年09
页码:
883-887
栏目:
血管介入
出版日期:
2020-09-25

文章信息/Info

Title:
Management of postoperative restenosis in patients with Budd-Chiari syndrome after interventional recanalization and its long-term follow-up results
作者:
张 伟 王巧争 陈晓伟 李启洋 韩金行 陈旭东 徐 克
Author(s):
ZHANG Wei WANG Qiaozheng CHEN Xiaowei LI Qiyang HAN Jinhang CHEN Xudong XU Ke.
Department of Interventional Radiology, Shenzhen Municipal People`s Hospital, Shenzhen, Guangdong Province 518020, China
关键词:
【关键词】 Budd-Chiari综合征 介入开通 再狭窄 远期随访 治疗策略
文献标志码:
A
摘要:
【摘要】 目的 探讨Budd-Chiari综合征患者介入开通术后再狭窄的治疗策略,评价远期随访结果。 方法 回顾性分析1983年11月至2013年12月60例原发性Budd-Chiari综合征介入开通术后出现再狭窄患者临床资料和随访结果。 结果 60例再狭窄患者根据初始开通术式分为单纯PTA治疗组(40例,其中混合型27例,下腔静脉型5例,肝静脉型8例)、PTA+支架植入组(20例,其中混合型13例,下腔静脉型6例,肝静脉型1例)。单纯PTA治疗组出院1年内、5年内、10年内发生再狭窄分别为15例(37.5%)、34例(85%)、38例(95%),PTA+支架植入组出院1年内、5年内、10年内发生再狭窄分别为10例(50%)、18例(90%)、19例(95%)。单纯PTA治疗组中13例拒绝治疗, 27例接受进一步治疗,其中5例随访中出现第2次再狭窄,2例第3次再狭窄,1例第4次再狭窄;PTA+支架植入组中9例拒绝治疗,10例仅接受单纯PTA,另1例接受PTA+支架植入,5例随访中发生第2次再狭窄,3例第3次再狭窄,1例第4次再狭窄。38例再狭窄后接受进一步治疗患者1年、5年、10年、20年、25年累积生存率分别为分别为100%、78.3%、78.3%、70.5%、70.5%,22例拒绝进一步治疗患者分别为72.7%、45.9%、30.6%、10.2%、NA(未获得),两部分患者间差异有显著统计学意义(P<0.001)。 结论 Budd-Chiari综合征患者介入开通术后远期随访非常重要。积极治疗再狭窄可改善患者预后。根据疗效逐步升级侵入性治疗策略,取得了满意的结果。

参考文献/References:

[1] European Association for the Study of the Liver. EASL clinical practice guidelines: vascular diseases of the liver[J]. J Hepatol, 2016, 64: 179- 202.
[2] Valla DC. Primary Budd- Chiari syndrome[J]. J Hepatol, 2009, 50: 195- 203.
[3] Zhang W, Qi X, Zhang X, et al. Budd- Chiari syndrome in China: a systematic analysis of epidemiological features based on the Chinese literature survey[J]. Gastroenterol Res Pract, 2015,2015: 738548.
[4] Mancuso A. Budd‐Chiari syndrome in the West and the East: same syndrome, different diseases[J]. Liver Int, 2019, 39: 2417.
[5] Seijo S, Plessier A, Hoekstra J, et al. Good long- term outcome of Budd- Chiari syndrome with a step- wise management[J]. Hepatology, 2013, 57: 1962- 1968.
[6] 中国医师协会腔内血管学专业委员会腔静脉阻塞专家委员会.下腔静脉与肝静脉“膜”与“节段”阻塞界定的专家共识[J]. 介入放射学杂志, 2016, 25:559- 561.
[7] Ding PX, Han XW, Liu C, et al. Long‐term outcomes of individualized treatment strategy in treatment of type Ⅰ Budd‐Chiari syndrome in 456 patients[J]. Liver Int, 2019, 39: 1577- 1586.
[8] Wei Z, Wang QZ, Chen XW, et al. Budd- Chiari syndrome in China: a 30- year retrospective study on survival from a single center[J]. World J Gastroenterol, 2018, 24: 1134- 1143.
[9] Han G, Qi X, Zhang W, et al. Percutaneous recanalization for Budd- Chiari syndrome: an 11- year retrospective study on patency and survival in 177 Chinese patients from a single center[J]. Radiology, 2013, 266: 657- 667.
[10]中国医师协会腔内血管学专业委员会腔静脉阻塞专家委员会.布- 加综合征亚型分型的专家共识[J]. 介入放射学杂志,2017, 26:195- 201.
[11] Zhang F, Wang C, Li Y. The outcomes of interventional treatment for Budd- Chiari syndrome: systematic review and meta- analysis[J]. Abdom Imaging, 2015, 40: 601- 608.
[12] Zhang QQ, Xu H, Zu MH, et al. Strategy and long- term outcomes of endovascular treatment for Budd- Chiari syndrome complicated by inferior vena caval thrombosis[J]. Eur J Vasc Endovasc Surg, 2014, 47: 550- 557.
[13] Ding PX, Li Z, Zhang SJ, et al. Outcome of the Z- expandable metallic stent for Budd- Chiari syndrome and segmental obstruction of the inferior vena cava[J]. Eur J Gastroenterol Hepatol, 2016, 28: 972- 979.
[14] Cheng DL, Zhu N, Xu H, et al. Outcomes of endovascular interventional therapy for primary Budd- Chiari syndrome caused by hepatic venous obstruction[J]. Exp Ther Med, 2018, 16: 4141- 4149.
[15] Valla DC, Cazals- Hatem D. Vascular liver diseases on the clinical side: definitions and diagnosis, new concepts[J]. Virchows Archiv, 2018, 473: 3- 13.
[16] Eapen CE, Velissaris D, Heydtmann M, et al. Favourable medium term outcome following hepatic vein recanalisation and/or transjugular intrahepatic portosystemic shunt for Budd- Chiari syndrome[J]. Gut, 2006, 55: 878- 884.
[17] Paul SB, Shalimar G, Sreenivas V, et al. Incidence and risk factors of hepatocellular carcinoma in patients with hepatic venous outflow tract obstruction[J]. Aliment Pharmacol Ther, 2015, 41: 961- 971.
[18] Vilgrain V, Paradis V, Van Wettere M, et al. Benign and malignant hepatocellular lesions in patients with vascular liver diseases[J]. Abdom Radiol(NY), 2018, 43: 1968- 1977.
[19] Gao XY, Gui E, Lu ZJ, et al. Risk factors of recurrence among 471 Chinese patients with Budd- Chiari syndrome[J]. Clin Res Hepatol Gastroenterol, 2015, 39: 620- 626.
[20] Sun J, Zhang Q, Xu H, et al. Clinical outcomes of warfarin anticoagulation after balloon dilation alone for the treatment of Budd- Chiari syndrome complicated by old inferior vena cava thrombosis[J]. Ann Vasc Surg, 2014, 28: 1862- 1868.

备注/Memo

备注/Memo:
(收稿日期:2019- 06- 30)
(本文编辑:边 佶)
更新日期/Last Update: 2020-09-15